Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive
NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the
R-CHOP regimen.